Sale!

Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test

7,500 د.إ

-25%

The Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test, available at DNA Labs UAE, is a comprehensive genetic test designed to aid in the diagnosis and management of various myeloid disorders. This test focuses on a range of myeloid conditions, including Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), and Juvenile Myelomonocytic Leukemia (JMML). By analyzing specific genetic mutations and alterations associated with these conditions, the panel provides valuable insights that can guide treatment decisions and prognosis assessments.

Conducted at the state-of-the-art facilities of DNA Labs UAE, the test employs cutting-edge sequencing technologies to ensure high accuracy and reliability of results. The cost of the Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test is 7500 AED, reflecting the comprehensive nature of the analysis and the advanced technology used.

This test represents a crucial tool in the personalized medicine approach for myeloid disorders, offering patients and healthcare providers a detailed genetic profile that can influence treatment strategies and ultimately improve patient outcomes.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test

Test Name: Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test

Components: Sodium Heparin Vacutainer (2ml) & EDTA Vacutainer (3ml)

Price: 7500.0 AED

Sample Condition: Bone marrow / Peripheral blood

Report Delivery: 2-3 weeks

Method: NGS (Next-Generation Sequencing)

Test Type: Genetics

Doctor: General Physician

Test Department: DNA Labs UAE

Pre Test Information

The Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

The Oncomine Myeloid Panel is a targeted next-generation sequencing (NGS) assay designed to detect mutations in genes associated with myeloid malignancies such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). The panel targets 52 genes including those commonly mutated in myeloid malignancies such as ASXL1, TP53, RUNX1, IDH1, IDH2, JAK2, FLT3, and NPM1. The assay also includes fusion detection for genes such as BCR-ABL1 and PDGFRB. The Oncomine Myeloid Panel provides a comprehensive and efficient approach to molecular profiling of myeloid malignancies, enabling clinicians to make more informed treatment decisions and improve patient outcomes.

Test Name Oncomine Myeloid Panel MDSMPNAMLCMLCMMLJMML Test
Components Sodium Heparin Vacutainer (2ml) & EDTA Vacutainer (3ml)
Price 7500.0 AED
Sample Condition Bone marrow \/ Peripheral blood
Report Delivery 2-3 weeks
Method NGS
Test type Genetics
Doctor General Physician
Test Department:
Pre Test Information Oncomine Myeloid Panel MDS,MPN,AML,CML,CMML,JMML] can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The Oncomine Myeloid Panel is a targeted next-generation sequencing (NGS) assay designed to detect mutations in genes associated with myeloid malignancies such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

The panel targets 52 genes including those commonly mutated in myeloid malignancies such as ASXL1, TP53, RUNX1, IDH1, IDH2, JAK2, FLT3, and NPM1. The assay also includes fusion detection for genes such as BCR-ABL1 and PDGFRB.

The Oncomine Myeloid Panel provides a comprehensive and efficient approach to molecular profiling of myeloid malignancies, enabling clinicians to make more informed treatment decisions and improve patient outcomes.